medigraphic.com
Órgano Oficial de la Asociación Mexicana de Infectología Pediátrica y la SLIPE.

2009, Number 87

<< Back Next >>

Rev Enfer Infec Pediatr 2009; 22.23 (87)

Kawasaki disease. A second-level hospital experience

Del Ángel AA, Rodríguez HR, Díaz LJL, Escárcega FP, Peredo RGH, Alonso AJG, Huerta ME, Galán HJC

Language: Spanish
References: 46
Page: 70-76
PDF size: 269.10 Kb.


ABSTRACT

Objective: To determine the prevalence of Kawasaki disease in a secondary hospital.
Materials and methods: A retrospective, descriptive, observational, study was conducted over a period of five years. We reviewed a total of 3,561 hospital discharges from the Department of Pediatrics and selected 15 patients diagnosed with Kawasaki disease.
Results: The prevalence of Kawasaki disease was 4.2% as the diagnosis of hospital discharge. The average age was 35 months, with a predominance of male and a ratio of 2.7:1. All expressed a fever and rash. Fourteen patients (93%) had conjunctival injection, changes in lips, mouth and limbs. The less frequent clinical manifestation was the cervical lymph nodes (33%). The sedimentation rate was elevated and C-reactive protein was reported positive. Hematologic abnormalities such as anemia, thrombocytosis and fever occurred in more than 90% of patients. The initial echocardiogram showed coronary ectasia in two patients, with regression of the same in the stage of convalescence. All patients received aspirin and 10 were administered intravenous immunoglobulin. There were no complications during follow-up.
Conclusions: Although the frequency of this type of vasculitis in Mexico is lower in comparison with other populations in the world, is the most common cause of acquired heart disease in our hospital, going far beyond the prevalence of rheumatic fever.


REFERENCES

  1. Kawasaki T. Acute febrile mucocuteneous lymph mode syndrome with lymphoid involvement with specific desquamation of the fingers and toes. Japan J Allergol 1967;16:118-22.

  2. Chang FY, Hwang B, Chen FJ, P, Lee PCH, Meng CL, Lu JH. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J 2006;25:241-45.

  3. Madeleine W, Cunningham, H.Cody M, Janet SH, Biagio AP, David KK, Donald YM. Anti-human cardiac myosin autoantibodies in Kawasaki syndrome. J Immunol 1999;1:1060-5.

  4. Newburger WJ, Takajashi M, Gerger AM, Gewitz HM, Tani YL, Burns JC, Ferrieri P, et al . Diagnosis, treatment and long term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease council on cardiovascular disease in the Young American Heart Association. Pediatrics 2004;114:1708-29.

  5. Rodríguez HR, Carbajal RL, Reynés MJ, García Piña C, Barrios FR, Zarco RJ, Belmont ML, Flores DJ. Enfermedad de Kawasaki. Acta Pediatr Mex 2001;22(2):97-103.

  6. Yanagawa H, Nakamura Y, Yashiro M, et al . Incidence survey of Kawasaki disease in 1997 and 1998 in Japan. Pediatrics 2001;107:e3.

  7. Chang RK. Hospitalizations for Kawasaki disease among children in the United States, 1988-1997. Pediatrics 2006;25:245-9.

  8. Rodríguez HR, Carbajal RL, Reynés MJ, Barrios FR, Zarco RJ. Abordaje diagnóstico y terapéutico de la enfermedad de Kawasaki. Acta Pediatr Mex 2006;27:36-49.

  9. Del Castillo MF. Enfermedad de Kawasaki. Semin Fund Esp Reumatol 2006;7:70-83.

  10. Prego Petit J. Enfermedad de Kawsaki. Arch Pediatr Urug 2003;74(2):99-113.

  11. Mariko F, Mariko K, Keiko H. Prediction of non responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. Suit Mun Hosp Osak Jap 1999;149:172-6.

  12. Frenkel SM, Ocaña GL, Bautista SA, Cortina RM, Cortina WJ. Enfermedad de Kawasaki: experiencia con ocho casos del Centro Médico ABC. Ann Med Hosp ABC 2004;49(2):66-72.

  13. Kawasaki T. Kawasaki disease. Acta Pediatr 1995;84:713-5.

  14. Machado K, Gutiérrez S, Pirez C. Enfermedad de Kawasaki asociada a virus de Epstein-Barr. Arch Pediatr Urug 2002;73(4):220-5.

  15. Rowley AH. Incomplete (atypical) Kawasaki disease. Pediatr Infect Dis J 2002;21:563-5.

  16. Mason WH, Takahashi M. Kawasaki syndrome. Clin Infect Dis 1999;28:169-87.

  17. Makhene MK, Diaz PS. Clinical presentations and complications of suspected measles in hospitalized children. Pediat Infect Dis J 1993;12:863-40.

  18. Newburger JW, Taubert KA, Shulman ST, et al . Summary and abstracts of the Seventh International Kawasaki Disease Symposium: December 4–7, 2001, Hakone, Japan. Pediatr Res 2003;53:153.

  19. Anderson MS, Burns J, Treadwell T, Pietra B, Glode M. Erythrocyte sedimentation rate and C-reactive protein discrepancy and high prevalence of coronary artery abnormalities in Kawasaki disease. Pediatr Infect Dis J 2001;20(7):698-702.

  20. Gómez RN, González RL, Sotelo CN, Cano RM, Durazo AM, Soto LV, Rojo VL. Enfermedad de Kawasaki resistente a dosis inicial de gammaglobulina intravenosa presentación de un caso. Bol Clin Hosp Infant Edo Son 2001;18:74-9.

  21. Weiss JE, Anne EB, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. The J of Rheumatol 2004;31:4.

  22. Burns JC, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.

  23. Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki syndrome. J Rheumatol 2004;31:808.

  24. Rodríguez HR, Carbajal RL, Reynés MJ, Mora TM, Zarco RJ. Enfermedad de Kawasaki complicada con aneurismas gigantes e infarto del miocardio. Acta Pediatr Mex 2006;27:128-32.

  25. Palazzi DL, McClain KL, Kaplan SL, Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003;22(7):663-6.

  26. Garty B, Mosseri R, Finkelstein Y. Guttate Psoriasis following Kawasaki disease. Pediatr Dermatol 2001;18(6):507-8.

  27. Rodríguez HR. Enfermedad de Kawasaki. Rev Enf Infec Ped 2001;57:1-2.

  28. Meissner HC, Leung DY. Síndrome de Kawasaki: ¿dónde están las respuestas? Pediatrics 2003;112:672-5.

  29. Rodríguez HR, Carbajal RL, Barrios FR, Zarco RJ. Síndrome de Kawasaki. Paciente de menor edad reportado en la casuística del Hospital Infantil de México Federico Gómez y revisión de la literatura. Bol Med Hosp Infant Mex 2002;59:752-4.

  30. Rodríguez HR. Enfermedad de Kawasaki. En: González-Saldaña N, Saltigeral-Simental P, Gómez-Barreto D (eds.). Atlas de enfermedades infecciosas en niños latinoamericanos. 1ª edición. Editorial Prado. México, 2005. p. 75-92.

  31. Rowley AH, Shulman ST. Síndrome de Kawasaki. Clin Pediatr Nort Am 1999:341-59.

  32. Burns JC, Wiggins JW, Toews WT, et al. Clinical spectrum of Kawasaki disease in infants younger than months of age. J Pediatr 1986:109:759-63.

  33. Rowley AH, Baker SC, Shulman ST, et al . Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J Infect Dis 2005;192:1757-66.

  34. Chang LY, Chiang BL, Kao CL, et al . Lack of association between infection with a novel human Coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan. J Infect Dis 2006;193:283-6.

  35. Shike H, Shimizu CH, Kanegaye JT, Foley J, Schnurr D, Wold LJ, Burns JC. Adenovirus, adeno-associated virus and Kawasaki disease. Pediatr Infect Dis J 2005;24(11):1011-4.

  36. Hiroko S, Chisato S, Kanegaye JT, Foly LJ, Schnurr PD, Wold LJ, Burns CJ. Adenovirus associated and Kawasaki disease. Pediatr Infect Dis J 2005;24:1011-4.

  37. Ambriz MM, Alvarado N. Enfermedad de Kawasaki. Alergia, Asma e Inmunol Pediatr 2000;9:96-9.

  38. Falcini F. Kawasaki disease. Current Opinion in Rheumatology 2006;18:33-8.

  39. Freeman AF, Shulman ST. Kawasaki disease: summary of the American Heart Association Guidelines. Am Fam Physician 2006;74:1141-8.

  40. Durongpisitkul K, Gururaj VJ, Park JM, et al . The prevention of coronary artery aneurysm in Kawasaki disease: a metaanalysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.

  41. Tse SML, Silverman ED, McCrindle BW, et al . Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002;140:450-5.

  42. Muta H, Ishii M, Egami K, et al . Early intravenous gammaglobulin treatment for Kawasaki disease: the Nationwide Surveys in Japan. J Pediatr 2004;144:496-9.

  43. Burns JC, Wiggins JW, Toews WT, et al. Clinical spectrum of Kawasaki disease in infants younger than months of age. J Pediatr 1986:109:759-63.

  44. Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463-4.

  45. Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J. Prediction of non-responsiveness to intravenous high-dose gammaglobulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6.

  46. Furusho K, Kamiya T, Nakano H, Kiyosawa K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T, et al . High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8.




2020     |     www.medigraphic.com